Actively Recruiting

Phase 1
Age: 18Years +
All Genders
NCT05650580

TR115 in Patients With Relapsed / Refractory Non-Hodgkin's Lymphoma or Advanced Solid Tumors

Led by Tarapeutics Science Inc. · Updated on 2024-05-14

26

Participants Needed

1

Research Sites

140 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

A phase 1 dose escalation and expanded cohort study of TR115 in the treatment of adult patients with relapsed/refractory non-hodgkin's lymphoma or advanced solid tumors.

CONDITIONS

Official Title

TR115 in Patients With Relapsed / Refractory Non-Hodgkin's Lymphoma or Advanced Solid Tumors

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Understand and agree to participate with signed informed consent
  • Male or female aged 18 years or older
  • Diagnosed with relapsed/refractory non-Hodgkin's lymphoma having received at least one prior systemic therapy or advanced solid tumors with no suitable standard treatment
  • Eastern Cooperative Oncology Group performance status of 2 or less at screening
  • Life expectancy of at least 3 months
  • Acceptable organ function including specific blood counts and liver and kidney tests within defined limits
  • Agree to use medically approved contraceptives during the study and for 6 months after the last dose
Not Eligible

You will not qualify if you...

  • Known or suspected allergy to the investigational drug components
  • Medical or surgical history that excludes participation per protocol
  • Previous medical treatments that exclude participation per protocol
  • Abnormal laboratory test results excluding participation
  • Pregnant or breastfeeding women or less than six months postpartum if not breastfeeding
  • Unable to complete the study due to poor compliance or other reasons, or deemed unsuitable by investigator judgment

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

The first affiliated hospital, Zhejiang university school of medicine

Hangzhou, Zhejiang, China, 310003

Actively Recruiting

Loading map...

Research Team

Y

Yang Shu, MD, BS.

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here